Helicobacter pylori
Conditions
Interventions
Experimental Group: Rabeprazole 20 mg twice daily (Bid) + Amoxicillin 1 g Bid + Clarithromycin 500 mg Bid + Potassium Citrate Bismuth 220 mg Bid + Brachyspira Yeast 0.25 g Bid. :Rabeprazole 20 mg twi
Control Group: Rabeprazole 20 mg Bid + Amoxicillin 1 g Bid + Clarithromycin 500 mg Bid + Potassium Citrate Bismuth 220 mg Bid.:Control Group: Rabeprazole 20 mg Bid + Amoxicillin 1 g Bid + Clarithromyc
Sponsors
The First Affiliated Hospital of Xiamen University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: a. Age 18-70 years. b. Confirmed presence of H. pylori infection through any of the following testing methods: 13C or 14C urea breath test, tissue pathology immunohistochemical staining, H. pylori culture, fecal H. pylori antigen testing. c. Patients undergoing their first H. pylori eradication treatment. d. Willingness to undergo H. pylori treatment and sign the relevant informed consent form.
Exclusion criteria
Exclusion criteria: a. Allergic to any drug used in the treatment plan. b. History of gastric surgery. c. Patients with active digestive ulcers accompanied by bleeding. d. Presence of severe dysfunction in vital organs such as respiratory, cardiac, liver, or kidney. e. Use of bismuth, antibiotics, and antimicrobial Chinese medicine in the 4 weeks prior to enrollment, and use of potassium-competitive acid blockers, PPIs, H2 receptor antagonists, and NSAIDs in the 2 weeks prior to treatment. f. Pregnant or lactating women. g. Individuals with alcohol or drug addiction, or severe neurocognitive disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter pylori eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Compliance;Intestinal microbiota; | — |
Countries
China
Contacts
Public ContactWei-Feng Huang
The First Affiliated Hospital of Xiamen University
Outcome results
None listed